The 16th Hemoglobin Switching Conference

描述（由申请人提供）： 一年两次的血红蛋白转换会议已经持续了29年，其巨大的成功有多种原因。首先，组织者（Stamatoyannopoulos，Higgs和Engel）努力识别并强调新发现，始终包括影响血红蛋白转换过程的新调查人员和研究。其次，这是唯一一个将基础科学家和临床医生聚集在一起讨论血红蛋白病的分子和发育起源以及治疗方法的场所（除了ASH，有超过10，000名与会者）。第三，这些会议在历史上已经演变成关注科学所引领的领域，因此仍然是非常热门的话题，并且不仅是首次展示第一个cDNA克隆、第一个克隆的人类基因组位点和促红细胞生成素结构的论坛，而且还启动了该领域许多当前领导者的职业生涯。（事实上，许多博士后研究员和年轻的教师在这次会议的全体会议上首次介绍了他们的工作）。第四，这是关于这一主题的唯一一次会议，通常来自美国内外的调查人员出席人数大致相等，这一事实反映在美国和欧洲之间一年两次的地点交替上。2008年，会议将在一个新的地点举行，即加利福尼亚州蒙特雷的阿西洛马会议中心，这是因为国际交通便利和经济实惠。

DESCRIPTION (provided by applicant): The biannual Hemoglobin Switching Conference has been ongoing for 29 years, and there are multiple reasons for its resounding success. First and foremost, the organizers (Stamatoyannopoulos, Higgs and Engel) strive to identify and then highlight new discoveries by always including new investigators and studies that impinge on the process of hemoglobin switching. Second, this is the only venue (other than ASH, with > 10,000 attendees) that brings together basic scientists and clinicians to discuss both the molecular and developmental origins of, and treatments for, hemoglobinopathies. Third, the meetings have historically morphed into focusing on wherever the science led, thus remaining extremely topical, and has not only been the forum for first presenting the first cDNA clones, the first cloned human genomic locus and the structure of erythropoietin, but it has also launched the careers of many of the current leaders in this field (indeed, numerous postdoctoral fellows and young faculty first presented their work in plenary sessions at this conference). Fourth, this is the only meeting on this topic that routinely has approximately equal attendance by investigators from both inside and outside the US, and this fact is reflected by the biannual alternation in site between the US and Europe. In 2008 the Conference will be held at a new venue, the Asilomar Conference Center in Monterrey, CA, because of both international accessibility and economy.